Autopsy report · NCT04741204

Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer

“Limited staff to carry out study”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Woman's

Sponsor type

University, hospital or other

Conditions

Breast Cancer Stage; Insulin Resistance; Racial Bias

Interventions

Metformin Extended Release Oral Tablet

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Worry Exposure for Generalized Anxiety Disorder
  “insufficient study staff” (74% match in meaning)
• Altruistic Decisions
  “Insufficient on-site staff to manage study” (73% match in meaning)
• Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
  “Due to limited resources available to conduct study” (67% match in meaning)
• Transcutaneous Intercostal Nerve Stimulation in Spinal Cord Injury
  “Lack of study staff” (67% match in meaning)
• StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients
  “study staff transition” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.